Cargando…

Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review

World Health Organization (WHO) declared coronavirus disease (COVID-19) a pandemic in March 2020. Currently almost every country in the world has reported cases with moderate to high mortality rates. The European Union (EU), the United States of America (USA) and the United Kingdom (UK) are the seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Richard, Seidu A., Kampo, Sylvanus, Esquijarosa Hechavarria, Maite
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731664/
https://www.ncbi.nlm.nih.gov/pubmed/33324480
http://dx.doi.org/10.4081/hr.2020.8630
_version_ 1783621943867473920
author Richard, Seidu A.
Kampo, Sylvanus
Esquijarosa Hechavarria, Maite
author_facet Richard, Seidu A.
Kampo, Sylvanus
Esquijarosa Hechavarria, Maite
author_sort Richard, Seidu A.
collection PubMed
description World Health Organization (WHO) declared coronavirus disease (COVID-19) a pandemic in March 2020. Currently almost every country in the world has reported cases with moderate to high mortality rates. The European Union (EU), the United States of America (USA) and the United Kingdom (UK) are the severely affected countries. Nevertheless, the WHO is very much concern about countries with weak health systems. The clinical characteristics of COVID-19 varies extensively, ranging from asymptomatic infections to severe as well as critical pneumonia with high mortality rates in the elderly and patients with co-morbid medical illness. Convalescent Plasma Therapy (CPT) has been successfully used in treating various viral disease outbreaks such as 1918 influenza pneumonia pandemic, poliomyelitis, measles, mumps, Machupo virus, Junin virus, Lassa virus, Ebola etc. High-titer specific antibodies maybe capable of binding to Coronavirus- 19 (CoV-19) and neutralize the viral particles, inhibit entry to uninfected cells, and trigger potent effector mechanisms such as complement activation as well as phagocytosis. Therefore, in most countries with very weak health systems with no Intensive Care Units (ICUs) or trained ICU physicians, early initiation of CPT for severely COVID- 19 patients may be rewarding. Therefore, solidarity control trials on CPT for COVID- 19 patients involving large number of patients are urgently needed.
format Online
Article
Text
id pubmed-7731664
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-77316642020-12-14 Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review Richard, Seidu A. Kampo, Sylvanus Esquijarosa Hechavarria, Maite Hematol Rep Review World Health Organization (WHO) declared coronavirus disease (COVID-19) a pandemic in March 2020. Currently almost every country in the world has reported cases with moderate to high mortality rates. The European Union (EU), the United States of America (USA) and the United Kingdom (UK) are the severely affected countries. Nevertheless, the WHO is very much concern about countries with weak health systems. The clinical characteristics of COVID-19 varies extensively, ranging from asymptomatic infections to severe as well as critical pneumonia with high mortality rates in the elderly and patients with co-morbid medical illness. Convalescent Plasma Therapy (CPT) has been successfully used in treating various viral disease outbreaks such as 1918 influenza pneumonia pandemic, poliomyelitis, measles, mumps, Machupo virus, Junin virus, Lassa virus, Ebola etc. High-titer specific antibodies maybe capable of binding to Coronavirus- 19 (CoV-19) and neutralize the viral particles, inhibit entry to uninfected cells, and trigger potent effector mechanisms such as complement activation as well as phagocytosis. Therefore, in most countries with very weak health systems with no Intensive Care Units (ICUs) or trained ICU physicians, early initiation of CPT for severely COVID- 19 patients may be rewarding. Therefore, solidarity control trials on CPT for COVID- 19 patients involving large number of patients are urgently needed. PAGEPress Publications, Pavia, Italy 2020-12-02 /pmc/articles/PMC7731664/ /pubmed/33324480 http://dx.doi.org/10.4081/hr.2020.8630 Text en ©Copyright: the Author(s) http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
spellingShingle Review
Richard, Seidu A.
Kampo, Sylvanus
Esquijarosa Hechavarria, Maite
Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review
title Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review
title_full Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review
title_fullStr Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review
title_full_unstemmed Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review
title_short Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review
title_sort elucidating the pivotal role of convalescent plasma therapy in critically ill covid-19 patients: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731664/
https://www.ncbi.nlm.nih.gov/pubmed/33324480
http://dx.doi.org/10.4081/hr.2020.8630
work_keys_str_mv AT richardseidua elucidatingthepivotalroleofconvalescentplasmatherapyincriticallyillcovid19patientsareview
AT kamposylvanus elucidatingthepivotalroleofconvalescentplasmatherapyincriticallyillcovid19patientsareview
AT esquijarosahechavarriamaite elucidatingthepivotalroleofconvalescentplasmatherapyincriticallyillcovid19patientsareview